Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,847JPY
24 May 2019
Change (% chg)

¥-25 (-0.65%)
Prev Close
¥3,872
Open
¥3,840
Day's High
¥3,879
Day's Low
¥3,829
Volume
4,393,500
Avg. Vol
8,253,716
52-wk High
¥4,943
52-wk Low
¥3,498

Latest Key Developments (Source: Significant Developments)

U.S. FDA Approves Gattex (Teduglutide) For Children With Short Bowel Syndrome
Friday, 17 May 2019 

May 17 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::U.S. FDA APPROVES GATTEX® (TEDUGLUTIDE) FOR CHILDREN 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS).TAKEDA PHARMACEUTICAL CO LTD - FDA APPROVED EXTENDING INDICATION OF GATTEX.  Full Article

Paulson & Co. Ups In Red Hat; Dissolves In Nielsen Holdings
Wednesday, 15 May 2019 

May 15 (Reuters) - Paulson & Co::PAULSON & CO. INC UPS SHARE STAKE IN RED HAT INC BY 11.5 PERCENT TO 420,500 SHARES - SEC FILING.PAULSON & CO. INC DISSOLVES SHARE STAKE IN NIELSEN HOLDINGS PLC - SEC FILING.PAULSON & CO. INC TAKES SHARE STAKE OF 13.2 MILLION SPONSORED ADS IN TAKEDA PHARMACEUTICAL CO LTD - SEC FILING.PAULSON & CO. INC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Takeda And Frazier Healthcare Partners Announce Collaboration To Launch Phathom Pharmaceuticals
Wednesday, 15 May 2019 

May 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND FRAZIER HEALTHCARE PARTNERS ANNOUNCE COLLABORATION TO LAUNCH PHATHOM PHARMACEUTICALS.TAKEDA PHARMACEUTICAL CO LTD - COLLABORATION TO LAUNCH PHATHOM PHARMACEUTICALS.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA HAS GRANTED A LICENSE TO PHATHOM FOR DEVELOPMENT AND EXCLUSIVE COMMERCIALIZATION RIGHTS TO VONOPRAZAN.TAKEDA PHARMACEUTICAL CO LTD - PHATHOM HAS COMPLETED A $90 MILLION CROSSOVER FINANCING AND $50 MILLION DEBT FACILITY.TAKEDA PHARMACEUTICAL CO LTD - DEAL INCLUDES UPFRONT CASH AND EQUITY, AS WELL AS FUTURE CASH MILESTONES AND ROYALTIES ON NET SALES.  Full Article

Takeda Pharmaceutical Co - Notice Concerning Issuance Of New Stocks Through Third-Party Allotment
Tuesday, 14 May 2019 

May 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE CONCERNING ISSUANCE OF NEW STOCKS THROUGH THIRD-PARTY ALLOTMENT.TO ISSUE NEW STOCKS WORTH TOTAL 49,009,300,000 YEN TO THE MASTER TRUST BANK OF JAPAN.ISSUANCE PRICE IS 4,318 YEN PER SHARE.ISSUING 11,350,000 COMMON SHARES.ALLOTMENT IS ASSOCIATED WITH CONTINUATION OF STOCK GRANT SYSTEM (GLOBAL LONG-TERM INCENTIVE PLAN) FOR COMPANY GROUP MANAGEMENT IN JAPAN AND OVERSEAS IN FISCAL 2019.  Full Article

Takeda says To Sell Xiidra To Novartis For Up To $5.3 Bln
Wednesday, 8 May 2019 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES.TAKEDA PHARMACEUTICAL CO LTD - AGREES TO SELL XIIDRA TO NOVARTIS FOR UP TO $5.3 BILLION.TAKEDA PHARMACEUTICAL CO LTD - COMPANY TO ALSO DIVEST TACHOSIL TO ETHICON FOR APPROXIMATELY $400 MILLION.TAKEDA PHARMACEUTICAL CO LTD - DOES NOT EXPECT THESE DIVESTITURES TO HAVE A MATERIAL IMPACT ON ITS FY2019 CONSOLIDATED EARNINGS FORECAST.TAKEDA PHARMACEUTICAL CO LTD - INTENDS TO USE PROCEEDS FROM DIVESTITURES TO REDUCE ITS DEBT.TAKEDA PHARMACEUTICAL - FY2019 FORECAST WILL BE UPDATED AT LATER DATE TO REFLECT DIVESTITURES ONCE RELIABLE ESTIMATE OF IMPACT CAN BE MADE.TAKEDA PHARMACEUTICAL CO LTD - RECORDED FULL YEAR ADJUSTED NET SALES FOR TACHOSIL OF APPROXIMATELY $155 MILLION IN FISCAL YEAR ENDED MARCH 31, 2018..TAKEDA - ENTERED LONG-TERM MANUFACTURING SERVICES AGREEMENT, UNDER WHICH CO TO CONTINUE TO MANUFACTURE TACHOSIL PRODUCTS AND SUPPLY THEM TO ETHICON.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA WILL MAINTAIN OWNERSHIP OF MANUFACTURING FACILITY IN LINZ, AUSTRIA.  Full Article

Novartis Says Entered Into Agreement With Takeda Pharmaceutical To Acquire Xiidra 5 pct Worldwide
Wednesday, 8 May 2019 

May 8 (Reuters) - Novartis AG ::REG-NOVARTIS TO ACQUIRE XIIDRA®, EXPANDING FRONT-OF-EYE PORTFOLIO AND STRENGTHENING LEADERSHIP IN EYE CARE.NOVARTIS AG - DEAL TERMS INCLUDE A USD 3.4 BILLION UPFRONT PAYMENT WITH POTENTIAL MILESTONE PAYMENTS OF UP TO USD 1.9 BILLION.NOVARTIS AG - AS PART OF AGREEMENT, NOVARTIS WILL BE TAKING ON APPROXIMATELY 400 EMPLOYEES ASSOCIATED WITH PRODUCT.NOVARTIS AG - ON DEAL CLOSE, NOVARTIS PLANS TRANSITION OF OPERATIONS AND INTEGRATION OF XIIDRA INTO ITS PHARMACEUTICALS PORTFOLIO.NOVARTIS AG SAYS ENTERED INTO AN AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED TO ACQUIRE ASSETS ASSOCIATED WITH XIIDRA 5% WORLDWIDE.  Full Article

Adimab Llc Says It Has Entered An Agreement To Transfer Adimab Platform To Takeda Pharmaceuticals
Wednesday, 8 May 2019 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ADIMAB LLC SAYS IT HAS ENTERED INTO AN AGREEMENT TO TRANSFER ADIMAB PLATFORM TO TAKEDA PHARMACEUTICALS.  Full Article

Emendo Biotherapeutics Enters Licensing Option Agreement With Takeda
Monday, 29 Apr 2019 

April 29 (Reuters) - EMENDO BIOTHERAPEUTICS ::EMENDO BIOTHERAPEUTICS ENTERS INTO LICENSING OPTION AGREEMENT WITH TAKEDA FOR ITS OMNI NUCLEASE PROGRAM.EMENDO BIOTHERAPEUTICS - WILL RECEIVE AN INVESTMENT IN CONVERTIBLE NOTES FROM TAKEDA VENTURES.  Full Article

Takeda Pharmaceutical Reports A 6.2 Pct Passive Stake In Hookipa Pharma As Of April 17
Friday, 26 Apr 2019 

April 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL CO LTD REPORTS A 6.2 PCT PASSIVE STAKE IN HOOKIPA PHARMA INC <<>> AS OF APRIL 17 - SEC FILING.  Full Article

Lupus Therapeutics Partners With Takeda On Phase 1 Trial
Friday, 1 Mar 2019 

March 1 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::LUPUS THERAPEUTICS PARTNERS WITH TAKEDA ON PHASE 1 TRIAL.LUPUS THERAPEUTICS PARTNERS WITH TAKEDA ON PHASE 1 TRIAL.LUPUS RESEARCH ALLIANCE - CO, LUPUS THERAPEUTICS ANNOUNCED COLLABORATION WITH TAKEDA PHARMA TO EVALUATE INVESTIGATIONAL BIOLOGIC TAK-079.  Full Article

Photo

Japan's Takeda expects binding offers for Latam business by end of May: sources

SAO PAULO Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.